WallStSmart

Dynavax Technologies Corporation (DVAX)vsZoetis Inc (ZTS)

VS

DVAX

Dynavax Technologies Corporation

NASDAQ

$15.50

0.00%

HEALTHCARE · Cap: $1.82B

ZTS

Zoetis Inc

NYSE

$72.86

+2.14%

HEALTHCARE · Cap: $29.50B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Zoetis Inc generates 2782% more annual revenue ($9.53B vs $330.51M). ZTS leads profitability with a 27.7% profit margin vs -0.1%. ZTS earns a higher WallStSmart Score of 58/100 (C).

DVAX

Hold

45

out of 100

Grade: D+

Growth: 3.3Profit: 3.0Value: 5.0Quality: 5.8
Piotroski: 4/9Altman Z: 0.98

ZTS

Buy

58

out of 100

Grade: C

Growth: 4.0Profit: 10.0Value: 6.0Quality: 7.0
Piotroski: 4/9Altman Z: 3.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DVAX.

ZTSUndervalued (+11.0%)

Margin of Safety

+11.0%

Fair Value

$144.59

Current Price

$72.86

$71.73 discount

UndervaluedFair: $144.59Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVAX0 strengths · Avg: 0/10

No standout strengths identified

ZTS5 strengths · Avg: 9.8/10
P/E RatioValuation
11.7x10/10

Attractively priced relative to earnings

Return on EquityProfitability
83.1%10/10

Every $100 of equity generates 83 in profit

Operating MarginProfitability
40.7%10/10

Strong operational efficiency at 40.7%

Altman Z-ScoreHealth
3.1410/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
27.7%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

DVAX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.2%4/10

0.2% revenue growth

EPS GrowthGrowth
0.7%4/10

0.7% earnings growth

Market CapQuality
$1.82B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.2%3/10

Operating margin of 0.2%

ZTS4 concerns · Avg: 3.0/10
Price/BookValuation
9.3x4/10

Trading at 9.3x book value

EPS GrowthGrowth
1.2%4/10

1.2% earnings growth

PEG RatioValuation
6.642/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : DVAX

DVAX has a balanced fundamental profile.

Bull Case : ZTS

The strongest argument for ZTS centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 27.7% and operating margin at 40.7%.

Bear Case : DVAX

The primary concerns for DVAX are Revenue Growth, EPS Growth, Market Cap.

Bear Case : ZTS

The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.

Key Dynamics to Monitor

DVAX profiles as a turnaround stock while ZTS is a declining play — different risk/reward profiles.

DVAX carries more volatility with a beta of 0.93 — expect wider price swings.

DVAX is growing revenue faster at 0.2% — sustainability is the question.

ZTS generates stronger free cash flow (538M), providing more financial flexibility.

Bottom Line

ZTS scores higher overall (58/100 vs 45/100), backed by strong 27.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Dynavax Technologies Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company is headquartered in Emeryville, California.

Zoetis Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.

Visit Website →

Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks

DVAX vs TAKDVAX vs TEVADVAX vs HLNDVAX vs UTHRDVAX vs VTRSZTS vs TAKZTS vs TEVAZTS vs HLNZTS vs UTHRZTS vs VTRS

Want to dig deeper into these stocks?

Full DVAX Analysis →Full ZTS Analysis →